TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give TuHURA Biosciences a “Moderate Buy” consensus: Five of six covering analysts recommend buying the stock, while one rates it a sell. The average 12-month price target is $9.00, versus a recent share price of $2.05.
• Institutional ownership remains limited: Several firms, including JPMorgan, Invesco and Virtu Financial, recently initiated positions, but institutional investors collectively own just 0.62% of the company.
• TuHURA shares were up 1.0%, with a market capitalization of about $130.65 million. The company reported a quarterly loss of $0.14 per share, slightly better than the $0.15 analyst consensus, while full-year losses are forecast at $0.55 per share.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.00.

HURA has been the subject of several research reports. Wall Street Zen downgraded shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday, May 31st. Citizens Jmp reaffirmed a "market outperform" rating and set a $9.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Friday, July 17th.

Institutional Investors Weigh In On TuHURA Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in TuHURA Biosciences in the 3rd quarter worth about $26,000. JPMorgan Chase & Co. acquired a new stake in shares of TuHURA Biosciences during the second quarter valued at about $27,000. Invesco Ltd. acquired a new stake in shares of TuHURA Biosciences during the second quarter valued at about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TuHURA Biosciences during the second quarter worth about $31,000. Finally, Two Sigma Securities LLC bought a new stake in shares of TuHURA Biosciences during the second quarter worth about $33,000. Institutional investors own 0.62% of the company's stock.

TuHURA Biosciences Stock Up 1.0%

Shares of NASDAQ HURA opened at $2.05 on Friday. The company has a current ratio of 0.18, a quick ratio of 0.18 and a debt-to-equity ratio of 0.20. The company has a market cap of $130.65 million, a price-to-earnings ratio of -3.80 and a beta of -0.02. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The stock has a 50-day moving average price of $2.19 and a two-hundred day moving average price of $2.17.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. As a group, analysts forecast that TuHURA Biosciences will post -0.55 earnings per share for the current fiscal year.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.